FDA Rejects Novartis’ Cox-2 Inhibitor, Prexige

Drug Industry Daily
A A
Novartis has received a not-approvable letter from the FDA for its Cox-2 inhibitor Prexige as a once-daily treatment for osteoarthritic pain, the company announced Sept. 27.

To View This Article:

Login

Subscribe To Drug Industry Daily